Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging

Nuclear Medicine and Biology

Volumn 38, Issue 2, 2011, Pages 223-233

  Orcutt, Kelly Davis ^a   Slusarczyk, Adrian L ^a   Cieslewicz, Maryelise ^a   Ruiz Yi, Benjamin ^a   Bhushan, Kumar R ^c   Frangioni, John V ^c   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

2D12.5; Antibody; DOTA; Pretargeting; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; GADOLINIUM CHELATE; GALLIUM; HAPTEN; INDIUM 111; LUTETIUM 177; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; YTTRIUM 86; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ARTICLE; BIOTINYLATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA CELL; CHELATION THERAPY; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING; DRUG HALF LIFE; DRUG RETENTION; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; MALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PREDICTION; RADIOGRAPHY; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; CELL LINE, TUMOR; CHELATING AGENTS; COLORECTAL NEOPLASMS; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KINETICS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR IMAGING; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SINGLE-CHAIN ANTIBODIES;

EID: 79551688075     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.08.013     Document Type: Article

References (56)

1. Axworthy D.B., Reno J.M., Hylarides M.D., Mallett R.W., Theodore L.J., Gustavson L.M., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000, 97:1802-1807.
2. Goldenberg D.M., Chatal J.F., Barbet J., Boerman O., Sharkey R.M. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther 2007, 2:19-31.
3. Goodwin D.A., Meares C.F., Watanabe N., Mctigue M., Chaovapong W., Ransone C.M., et al. Pharmacokinetics of pretargeted monoclonal-antibody 2d12.5 and Y-88 Janus-2-(P-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in Balb/C mice with Khjj mouse adenocarcinoma - a model for Y-90 radioimmunotherapy. Cancer Res 1994, 54:5937-5946.
4. Liu G., Dou S., Mardirossian G., He J., Zhang S., Liu X., et al. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin Cancer Res 2006, 12:4958-4964.
5. Pantelias A., Pagel J.M., Hedin N., Saganic L., Wilbur S., Hamlin D.K., et al. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 2007, 109:4980-4987.
6. Forster G.J., Santos E.B., Smith-Jones P.M., Zanzonico P., Larson S.M. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 2006, 47:140-149.
7. Hamblett K.J., Kegley B.B., Hamlin D.K., Chyan M.K., Hyre D.E., Press O.W., et al. A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem 2002, 13:588-598.
8. Foulon C.F., Alston K.L., Zalutsky M.R. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl Med Biol 1998, 25:81-88.
9. Stickney D.R., Anderson L.D., Slater J.B., Ahlem C.N., Kirk G.A., Schweighardt S.A., et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991, 51:6650-6655.
10. Le Doussal J.M., Martin M., Gautherot E., Delaage M., Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989, 30:1358-1366.
11. Janevik-Ivanovska E., Gautherot E., Hillairet de Boisferon M., Cohen M., Milhaud G., Tartar A., et al. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem 1997, 8:526-533.
12. Sharkey R.M., McBride W.J., Karacay H., Chang K., Griffiths G.L., Hansen H.J., et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003, 63:354-363.
13. Kraeber-Bodere F., Rousseau C., Bodet-Milin C., Ferrer L., Faivre-Chauvet A., Campion L., et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 2006, 47:247-255.
14. Corneillie T.M., Whetstone P.A., Lee K.C., Wong J.P., Meares C.F. Converting weak binders into infinite binders. Bioconjug Chem 2004, 15:1389-1391.
15. Penfield J.G., Reilly R.F. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. Semin Dial 2008, 21:129-134.
16. Camera L., Kinuya S., Garmestani K., Wu C., Brechbiel M.W., Pai L.H., et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 1994, 35:882-889.
17. Byegard J., Skarnemark G., Skalberg M. The stability of some metal EDTA, DTPA and DOTA complexes: application as tracers in groundwater studies. J Radioanal Nucl Chem 1999, 241:281-290.
18. Le Mignon M.M., Chambon C., Warrington S., Davies R., Bonnemain B. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 1990, 25:933-937.
19. Lubic S.P., Goodwin D.A., Meares C.F., Song C., Osen M., Hays M. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma. J Nucl Med 2001, 42:670-678.
20. Corneillie T.M., Whetstone P.A., Fisher A.J., Meares C.F. A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series. J Am Chem Soc 2003, 125:3436-3437.
21. Love R.A., Villafranca J.E., Aust R.M., Nakamura K.K., Jue R.A., Major J.G., et al. How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate. Biochemistry 1993, 32:10950-10959.
22. Blake D.A., Jones R.M., Blake R.C., Pavlov A.R., Darwish I.A., Yu H. Antibody-based sensors for heavy metal ions. Biosens Bioelectron 2001, 16:799-809.
23. Thurber G.M., Zajic S.C., Wittrup K.D. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007, 48:995-999.
24. Cox J.P.L., Craig A.S., Helps I.M., Jankowski K.J., Parker D., Eaton M.A.W., et al. synthesis of C-functionalized and N-functionalized derivatives of 1,4,7-triazacyclononane-1,4,7-triyltriacetic acid (NOTA), 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetrayltetra-acetic acid (DOTA), and diethylenenetriaminepenta-acetic acid (DTPA) - bifunctional complexing agents for the derivatization of antibodies. J Chem Soc, Perkin Trans 1 1990, 2567-2576.
25. Takenouchi K., Watanabe K., Kato Y., Koike T., Kimura E. Novel bifunctional macrocyclic chelating-agents appended with a pendant-type carboxymethylamino ligand and nitrobenzyl group and stability of the Y-88(III) complexes. J Org Chem 1993, 58:1955-1958.
26. Ashweek N.J., Coldham I., Haxell T.F.N., Howard S. Preparation of diamines by lithiation-substitution of imidazolidines and pyrimidines. Org Biomol Chem 2003, 1:1532-1544.
27. Chao G., Lau W.L., Hackel B.J., Sazinsky S.L., Lippow S.M., Wittrup K.D. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006, 1:755-768.
28. Hackel B.J., Kapila A., Wittrup K.D. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 2008, 381:1238-1252.
29. Graff C.P., Chester K., Begent R., Wittrup K.D. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel 2004, 17:293-304.
30. Orcutt K.D., Ackerman M.E., Cieslewicz M., Quiroz E., Slusarczyk A.L., Frangioni J.V., et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010, 23:221-228.
31. Humblet V., Misra P., Frangioni J.V. An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media Mol Imaging 2006, 1:196-211.
32. Misra P., Humblet V., Pannier N., Maison W., Frangioni J.V. Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med 2007, 48:1379-1389.
33. Schmidt M.M., Thurber G.M., Wittrup K.D. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008.
34. Fenwick J.R., Philpott G.W., Connett J.M. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor uptake. Int J Cancer 1989, 44:1017-1027.
35. Knox S.J., Goris M.L., Tempero M., Weiden P.L., Gentner L., Breitz H., et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000, 6:406-414.
36. Shih L.B., Thorpe S.R., Griffiths G.L., Diril H., Ong G.L., Hansen H.J., et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994, 35:899-908.
37. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
38. Corneillie T.M., Fisher A.J., Meares C.F. Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system. J Am Chem Soc 2003, 125:15039-15048.
39. Reiter Y., Brinkmann U., Lee B., Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 1996, 14:1239-1245.
40. Moreau J., Guillon E., Pierrard J.C., Rimbault J., Port M., Aplincourt M. Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DOTA)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS. Chemistry 2004, 10:5218-5232.
41. Liu G., Dou S., He J., Liu X., Rusckowski M., Hnatowich D.J. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 2007, 34:237-246.
42. Zhu H., Jain R.K., Baxter L.T. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med 1998, 39:65-76.
43. Siegel J.A., Stabin M.G. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994, 35:152-156.
44. Butlin N.G., Meares C.F. Antibodies with infinite affinity: origins and applications. Acc Chem Res 2006, 39:780-787.
45. Aime S., Barge A., Botta M., Fasano M., Ayala J.D., Bombieri G. Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA. Inorg Chim Acta 1996, 246:423-429.
46. Cosentino U., Villa A., Pitea D., Moro G., Barone V., Maiocchi A. Conformational characterization of lanthanide(III)-DOTA complexes by ab initio investigation in vacuo and in aqueous solution. J Am Chem Soc 2001, 124:4901-4909.
47. Aime S., Botta M., Fasano M., Marques M.P.M., Geraldes C.F.G.C., Pubanz D., et al. Conformational and coordination equilibria on DOTA complexes of lanthanide metal ions in aqueous solution studied by 1H-NMR spectroscopy. Inorg Chem 1997, 36:2059-2068.
48. Liu S., He Z., Hsieh W., Fanwick P.E. Synthesis, characterization, and x-ray crystal structure of In(DOTA-AA) (AA=p-aminoanilide): A model for 111In-labeled DOTA-biomolecule conjugates. Inorg Chem 2003, 42:8831-8837.
49. Heppeler A., Froidevaux S., Macke H.R., Jermann E., Behe M., Powell P., et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999, 5:1974-1981.
50. Midelfort K.S., Hernandez H.H., Lippow S.M., Tidor B., Drennan C.L., Wittrup K.D. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J Mol Biol 2004, 343:685-701.
51. DeNardo D.G., Xiong C.Y., Shi X.B., DeNardo G.L., DeNardo S.J. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001, 16:525-535.
52. Marvin J.S., Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005, 26:649-658.
53. Schneider D.W., Heitner T., Alicke B., Light D.R., McLean K., Satozawa N., et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med 2009, 50:435-443.
54. Olafsen T., Kenanova V.E., Wu A.M. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 2006, 1:2048-2060.
55. Barbet J., Peltier P., Bardet S., Vuillez J.P., Bachelot I., Denet S., et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998, 39:1172-1178.
56. Orcutt K.D., Nasr K.A., Whitehead D.G., Frangioni J.V., Wittrup K.D. Biodistribution and clearance of small molecule hapten chelate for pretargeted radioimmunotherapy. Mol Imaging Biol 2010, doi:10.1007/s11307-010-0353-6 [Epub ahead of print].